Lentiviral Vectors Articles & Analysis
8 news found
Viral vector is a critical component used in the manufacturing of CAR T cells, and third-generation lentiviral vectors offer improved safety over earlier generations1. The amended license will enable Chimeric to manufacture clinical-grade lentiviral vector for use in its planned phase 1 study of CHM 2101 (CDH17 ...
Moreover, they point to the great possibilities lentiviral-based gene therapies can offer for patients with devastating diseases,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. ...
” Data collected from six gene therapy study groups in mice show: Stable engraftment up to eight months after gene therapy, with median vector copy numbers (VCN) between 1.9 and 3.6 per diploid genome (n=9-13 per group) in bone marrow among all study groups. ...
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers ...
About CellVec CellVec is the first CDMO in Southeast Asia GMP-certified for the production of viral vectors for gene therapy as an active pharmaceutical ingredient. Its manufacturing facility is built to comply with PIC/S, US FDA and EU GMP specifications for viral vectors, upholding quality standards of viral vector production. Specialising in ...
Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of certain adult patients with relapsed or refractory multiple myeloma, a blood cancer formed by malignant plasma cells and typically originating in the bone marrow. The lentiviral vector used to engineer patients’ T cells was developed ...
About Catalent Cell & Gene Therapy With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. ...
Naru Intelligence: Artificial intelligence systems to improve results in oncology and other chronic diseases VIVEbiotech: Production of lentiviral vectors for gene therapy clinical trials to treat diseases of genetic origin, cancer, rare diseases or Parkinson's Specifically, the award for the best business idea or project in this edition went to a novel ...